Kyorin Pharmaceutical Co (Kyorin Pharmaceutical Co) Long-Term Capital Lease Obligation : $0.0 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Kyorin Pharmaceutical Co Long-Term Capital Lease Obligation?

Kyorin Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.0 Mil.

Kyorin Pharmaceutical Co's annual Long-Term Capital Lease Obligation declined from Mar. 2022 ($2.9 Mil) to Mar. 2023 ($1.5 Mil) and declined from Mar. 2023 ($1.5 Mil) to Mar. 2024 ($0.8 Mil).

Kyorin Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Long-Term Capital Lease Obligation Chart

Kyorin Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

5.00

3.76

2.88

1.55

0.83

Kyorin Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.55	-	-	-	0.83

Kyorin Pharmaceutical Co (OTCPK:KYRNF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Kyorin Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyorin Pharmaceutical Co (Kyorin Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (OTCPK:KYRNF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

4569:Japan

Address

6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311

Website

https://www.kyorin-pharm.co.jp

Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (Kyorin Pharmaceutical Co) Headlines

No Headlines